AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03690934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistula-tract laser closure (FiLAC™)
Description: The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
Study NCT02989779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK1 Antagonist
Study NCT02989779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NK1 Antagonist
Study NCT03690934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar coagulation of fistulous tract
Description: The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
Study NCT03644069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
Study NCT03644069 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SQ injections: 32 in total, at twice weekly intervals
Study NCT02436083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic (use of penicilline, unacid, cefuroxime)
Description: prophylactic antibiotics
Study NCT00426322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bovine bone mineral particles (Bio-Oss®)
Description: bovine bone mineral particles used for sinus augmentation prior to dental implant placement
Study NCT01678443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: indium In 111 anti-CD45 monoclonal antibody BC8
Description: Given IV
Study NCT01678443 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Description: Given IV
Study NCT01678443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00894634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate
Study NCT03413254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine follow-up
Description: Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
Study NCT03413254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up
Description: Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
Study NCT03413254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second look DLS
Description: Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
Study NCT03413254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second look DLS
Description: Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
Study NCT03413254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third look DLS
Description: Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
Study NCT00708526 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care for phase one anesthesia care
Description: Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
Study NCT00708526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick Emergence Device
Description: The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
Study NCT01478113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine/dextroamphetamine
Description: The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
Study NCT01478113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
Study NCT01478113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Well-being therapy
Description: Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
Study NCT01478113 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Well-being therapy
Description: Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
Study NCT02989779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Study NCT02989779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT04052386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICCS
Description: Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
Study NCT03781089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Powder Product
Description: Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
Study NCT00714532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expert System Only
Description: Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
Study NCT00714532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Expert System
Description: The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction
Study NCT03355755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT with SmartAssist software
Description: Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
Study NCT02734108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
Study NCT01400230 — intervention group
Intervention type: PROCEDURE
Intervention: diagnostic procedures CCTA, CAG, IVUS and FFR
Description: Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
Study NCT02629055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory EMG
Description: Titration of non-invasive ventilation on surface respiratory muscle activity
Study NCT00041756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-530742
Description: One 25 mg PG-530742 tablet, twice daily for for one year
Study NCT00041756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet, twice daily for for one year
Study NCT00041756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PG-530742
Description: One 50 mg PG-530742 tablet, twice daily for for one year
Study NCT00041756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PG-530742
Description: 100 mg PG-530742 tablet, twice a day for one year
Study NCT00041756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg PG-530742
Description: 200 mg PG-530742 tablet, twice a day for one year
Study NCT01653808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elisio-210H
Description: comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
Study NCT01653808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-210H
Description: comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
Study NCT01653808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional hemodialysis
Description: comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
Study NCT01653808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: on line hemodiafiltration
Description: comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
Study NCT04421742 — intervention group
Intervention type: DRUG
Intervention: Beclomethasone Dipropionate/Formoterol Fumarate
Description: BDP/FF NEXThaler® 100/6 μg b.i.d.
Study NCT02799303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI
Description: Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
Study NCT02799303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSA testing
Description: Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
Study NCT04399551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB OLI
Description: CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
Study NCT04399551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA 600 mg will be administered as intramuscular (IM) injection.
Study NCT04399551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV OLI
Description: RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
Study NCT04399551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA 900 mg will be administered as IM injection.
Study NCT04399551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Quality Improvement (CQI) calls
Description: CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
Study NCT03880695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib+ Liposomal Doxorubicin
Description: Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
Study NCT00742820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Acetate Oral Solution 667 mg per 5 mL
Description: Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
Study NCT00742820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Acetate 667 mg GelCaps
Description: Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
Study NCT00742820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium Citrate 950 mg Caplets
Description: Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
Study NCT01014975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
Study NCT01014975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
Study NCT01014975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
Study NCT02122341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BackStop
Description: BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
Study NCT01469455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT01
Description: DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions.
Study NCT00633932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg once daily
Study NCT00633932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 mg once daily
Study NCT00633932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20mg once daily
Study NCT03248609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milano grapes
Description: Milano grapes to test post-prandial glycemic response
Study NCT03248609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table grapes
Description: Table grapes to test post-prandial glycemic response
Study NCT03248609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grape juice
Description: Grape juice to test post-prandial glycemic response
Study NCT03248609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose beverage
Description: Standardized glucose beverage to test post-prandial glycemic response
Study NCT00724139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: : APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel
Description: training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
Study NCT02105441 — intervention group
Intervention type: DEVICE
Intervention: Cochlear implant
Description: Implantable hearing device
Study NCT02611050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Multi-vessel Coronary Artery Disease Option Grid
Description: The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
Study NCT02611050 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
Study NCT01118455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Description: Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
Study NCT01118455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Epileptic Drug (AED)
Description: Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
Study NCT02751918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
Study NCT02751918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
Study NCT02852018 — intervention group
Intervention type: GENETIC
Intervention: Identification of genetic polymorphisms
Study NCT05429658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
Study NCT00981396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
Study NCT00981396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Description: CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.